Vistin Pharma ASA is a Norway-based holding company, which operates through its subsidiary Vistin Pharma AS. The Company is engaged in the pharmaceuticals industry. The Company is a producer and supplier of Active Pharmaceutical Ingredients (APIs), which are used in medications for diabetes. Vistin Pharma offering such products: Metformin HCl (API); Metformin DC (direct compressible granules); Customized Particle Distribution (PSD) and Premix (Metformin + MgSt, can be delivered on-request). The Companyâ€™s customers are pharmaceutical companies worldwide.

Employees

Sector

Pharmaceuticals

Calendar

10-28 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
26-08-21	NOK 19.30	0.00%	20,955
26-08-20	NOK 19.30	-4.46%	101,460
26-08-19	NOK 20.20	+0.50%	2,831
26-08-18	NOK 20.10	0.00%	5,533
26-08-17	NOK 20.10	-0.50%	1,402

Real-time Oslo Bors

More quotes

Market Closed - Oslo Bors 10:45:00 2026-08-21 EDT			5-day change	1st Jan Change
19.30 ^NOK	0.00%		-4.46%	-7.21%

08-20	Vistin Pharma ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	Vistin Pharma ASA, Q2 2026 Earnings Call, Aug 20, 2026

Market Cap	856M 92M 78.81M 73.74M 67.5M 127M 8.8B 128M 871M 340M 4.42B 345M 338M 14.63B	P/E 2024	16.7x	P/E 2025	12.3x
Enterprise Value	841M 90.4M 77.44M 72.46M 66.32M 124M 8.65B 126M 856M 334M 4.35B 339M 332M 14.37B	EV / Sales 2024	2.42x	EV / Sales 2025	2.01x
Free-Float	41.06%	Yield 2024	5.27%	Yield 2025	7.21%

08-20	Vistin Pharma ASA Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-20	Vistin Pharma ASA, Q2 2026 Earnings Call, Aug 20, 2026
04-24	Vistin Pharma ASA Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-24	Vistin Pharma ASA, Q1 2026 Earnings Call, Apr 24, 2026
04-24	Vistin Pharma Q1 net profit of NOK 21.5 mln	RE
02-12	Vistin Pharma preliminary Q4 ebitda at NOK 26 mln	RE
02-12	Vistin Pharma ASA, Q4 2025 Earnings Call, Feb 12, 2026
02-12	Vistin Pharma ASA Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-12	Vistin Pharma ASA Proposes Ordinary Cash Dividend for 2025, Payable on or About 29 May 2026 and November 2026 Respectively	CI
25-10-31	Vistin Pharma ASA Reports Production Results for the Third Quarter Ended September 30, 2025	CI
25-10-31	Vistin Pharma ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-31	Vistin Pharma ASA, Q3 2025 Earnings Call, Oct 31, 2025
25-10-31	Vistin Pharma Q3 EBITDA falls to NOK 28 mln	RE

08-20	Vistin Pharma ASA: Second quarter and YTD 2026 financial results	GL
08-13	Vistin Pharma ASA: Invitation to Q2 2026 conference call	GL
05-22	Ex dividend NOK 1.00 today	GL
05-20	Vistin Pharma ASA: Minutes from the annual general meeting 2026	GL
05-08	Vistin Pharma : Redeye Theme Event – Diabetes 2026	PU

Vistin Pharma ASA Stock

Stocks

VISTN

NO0010734122

Pharmaceuticals

Valuation: Vistin Pharma ASA

Chart: Vistin Pharma ASA

Latest news : Vistin Pharma ASA

Last Transcript: Vistin Pharma ASA

Press Releases: Vistin Pharma ASA

Quotes and Performance

Course Extremes

Managers and Directors: Vistin Pharma ASA

Latest insider transactions

Generic Pharmaceuticals

Financials

Company Profile

Quotes

1 week	-4.46%
Current month	-4.93%
1 month	-5.85%
3 months	-8.96%
6 months	-9.39%
Current year	-7.21%

1 week	17.7	20.5
1 month	17.7	20.5
Current year	17.7	23.5
1 year	17.7	24.3
3 years	17.7	28.8
5 years	11.25	28.8
10 years	5	29.45

Manager	Title	Age	Since
Magnus Tolleshaug CEO	Chief Executive Officer	-	2023-12-31
Alexander Karlsen DFI	Director of Finance/CFO	-	2020-03-01
Vegard Heggem COO	Chief Operating Officer	-	-

Director	Title	Age	Since
Øyvin Anders Brøymer CHM	Chairman	78	2020-05-31
Kari Eian Krogstad BRD	Director/Board Member	62	2019-12-31
Kjell-Erik Nordby BRD	Director/Board Member	69	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/18/23	SAGA PURE ASA	Buy	Company	100,000	0.2255%
5/31/23	Magnus Tolleshaug	Buy	Chief Executive Officer	15,000	0.0338%
5/30/23	Øystein Stray Spetalen	Buy	Director	250,000	0.5638%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VISTIN PHARMA ASA	0.00%	-4.46%	-18.91%	-16.45%	92M
SUN PHARMACEUTICAL INDUSTRIES LTD.	-0.08%	-1.43%	+15.87%	+67.24%	47.71B
OTSUKA HOLDINGS CO., LTD.	-3.21%	+1.37%	+51.19%	+124.26%	40.3B
CIPLA LIMITED	-0.40%	-1.23%	-10.08%	+17.30%	12.09B
ZYDUS LIFESCIENCES LIMITED	+1.11%	-1.34%	+13.27%	+72.07%	11.68B
KRKA, D. D.	+0.19%	+0.58%	+30.98%	+151.21%	9.19B
GEDEON RICHTER	-0.39%	-0.92%	+20.49%	+39.85%	7.57B
ONO PHARMACEUTICAL CO., LTD.	-1.35%	+0.74%	+47.38%	-12.13%	7.24B
GLENMARK PHARMACEUTICALS LIMITED	-0.64%	-0.02%	+19.65%	+205.39%	6.84B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-5.36%	-6.36%	-38.04%	+19.49%	5.42B
Average	-1.01%	-1.45%	+13.18%	+66.82%	14.81B
Weighted average by Cap.	-1.14%	-0.57%	+24.05%	+83.56%

	2024	2025
Net sales	430M 46.17M 39.55M 37.01M 33.87M 63.57M 4.42B 64.41M 437M 171M 2.22B 173M 170M 7.34B	452M 48.62M 41.65M 38.97M 35.67M 66.95M 4.65B 67.83M 460M 180M 2.34B 183M 179M 7.73B
Net income	62.75M 6.75M 5.78M 5.41M 4.95M 9.29M 645M 9.41M 63.88M 24.91M 324M 25.33M 24.78M 1.07B	74.75M 8.04M 6.88M 6.44M 5.9M 11.06M 769M 11.21M 76.09M 29.67M 386M 30.17M 29.52M 1.28B
Net Debt	-10.55M -1.13M -971K -909K -832K -1.56M -109M -1.58M -10.74M -4.19M -54.51M -4.26M -4.17M -180M	-14.91M -1.6M -1.37M -1.28M -1.18M -2.21M -153M -2.24M -15.18M -5.92M -77.03M -6.02M -5.89M -255M